Pyrotinib/Areni Standard Usage and Dosage Guide

Pyrotinib Maleate (Pyrotinib Maleate) is an oral small molecule HER2-targeted drug. Its standard dose is 400 mg once a day. It is recommended to take it orally within 30 minutes after a meal to ensure optimal absorption and bioavailability of the drug in the gastrointestinal tract. Patients should try to take the medicine at the same time every day, continuously, and every 21 days constitutes a complete treatment cycle. The drug is easy to take and facilitates long-term maintenance treatment for patients, thereby continuously inhibiting the HER2 signaling pathway and delaying tumor progression.

If a breast cancer patient forgets to take medication on a certain day, there is no need to make up for the missing dose, and the patient should continue to take the medication as originally planned at the next medication time. This medication management method can avoid the risk of adverse reactions caused by drug overdose or fluctuations in blood drug concentration. In clinical practice, regular medication is essential to maintain stable blood drug levels and therapeutic effects. Depending on the individual patient's condition, doctors may combine trastuzumab or chemotherapy drugs for combined treatment to enhance the anti-tumor effect. In the combination treatment regimen, the dose of pyrotinib does not need to be adjusted with the combined drug, making it easier for patients to self-manage in a home environment.

During long-term medication, patients should pay attention to possible side effects of the medication, such as diarrhea, fatigue, hand-foot syndrome and hematological abnormalities, and conduct regular blood and liver function tests. For patients who experience moderate to severe adverse reactions, doctors can make dose adjustments or short-term discontinuation according to the guidelines. The combination of reasonable dosage and standardized medication management enables pyrotinib to show good efficacy and controllable safety in patients withHER2-positive breast cancer.

Generally speaking, the standard usage and dosage guidelines of pyrotinib emphasize daily oral fixed dose, taking after meals and regular management to ensure that the drug can fully exert its HER2 targeting effect and provide a sustainable treatment plan for patients with recurrence, metastasis and brain metastasis.

Reference materials:https://www.drugs.com